Abnormal Cannabidiol (Abn-CBD) Research Dashboard
Double-blind human trials
Clinical human trials
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 12 studies associated with Abnormal Cannabidiol (Abn-CBD).
Here is a small sampling of Abnormal Cannabidiol (Abn-CBD) studies by title:
- Neuroprotection of Cannabidiol, Its Synthetic Derivatives and Combination Preparations against Microglia-Mediated Neuroinflammation in Neurological Disorders
- A molecular explanation of cardiovascular protection through abnormal cannabidiol: Involving the dysfunctional β-adrenergic and ATP-sensitive K+ channel activity in cardiovascular compromised preterm infants
- A study of abnormal cannabidiols system-mediated cardiovascular protection in disrupted gut/brain axis associated depression
- The Atypical Cannabinoid Abn-CBD Reduces Inflammation and Protects Liver, Pancreas, and Adipose Tissue in a Mouse Model of Prediabetes and Non-alcoholic Fatty Liver Disease
- CRISPR/Cas9 gene editing demonstrates metabolic importance of GPR55 in the modulation of GIP release and pancreatic beta cell function
Components of the Abnormal Cannabidiol (Abn-CBD) Research Dashboard
- Top medical conditions associated with Abnormal Cannabidiol (Abn-CBD)
- Proven effects in clinical trials for Abnormal Cannabidiol (Abn-CBD)
- Receptors associated with Abnormal Cannabidiol (Abn-CBD)
- Individual study details for Abnormal Cannabidiol (Abn-CBD)
Ready to become a subscriber? Go to our PRICING page.
Members can filter by the following criteria:
- Study Type
- Organ Systems
- Study Result
- Year of Publication
Overview - Abnormal Cannabidiol (Abn-CBD)
Description of Abnormal Cannabidiol (Abn-CBD)
Abnormal CBD is a synthetic isomer of CBD that was discovered in 1974. One of its known physiological properties is its ability to produce vasodilation by a non-CB1/CB1 mechanism.
Abnormal cannabidiol, Resorcinol (and numerous others)
IUPAC Name: 4-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
Molecular Formula: C21H30O2
Abnormal Cannabidiol (Abn-CBD) Properties and Effects
• Vasodilation (hypotension)
Abnormal Cannabidiol (Abn-CBD) Receptor Binding
Endocannabinoid system (ECS):
Abnormal CBD has not been shown to bind with either CB1 and CB2.
Exact binding mechanisms are not fully understood.
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.